European Expert Consortium Combines Forces to Develop a Novel Pandemic Influen...(get _new http://www.akzonobel.com . (...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Date:9/25/2007
get="_new">http://www.akzonobel.com.
(*) Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
'/>"/>
| SOURCE N.V. Organon Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
6. Tired of the spin? ExpertVoter website makes candidate selection easier
7. Innovation expert speaks on the business-IT balancing act
8. Brady appoints GE efficiency expert as CTO
9. Innovation expert says Milwaukee has all the tools
10. Microsoft rewards Berbee for project management expertise
11. Sonic Foundry creates search engine for 7,000 expert video presentations
Post Your Comments:
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3
[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening[0] Vivakor Confirms Record Date of Stock Dividend
Other Biology Technology:NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer TreatmentArius announces new findings in Trop-2 and CD59 CANCER antibody programs
Breaking Biology News(10 mins):Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stem cells battle for space 2Lee County Schools 22Lightens Up 22 by 2000 lbs and saves big 54159 1Lee County Schools 22Lightens Up 22 by 2000 lbs and saves big 54159 2Pharmaburst 28R 29 500 3A Optimized Evolutionary ODT Performance 13492 1ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4844 1ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4844 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4844 3ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4844 4ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4844 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |